Financials in USD. Standardized financial statements.
A compact view of how Recce Pharmaceuticals Ltd turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $7.51M | $6.85M | $4.37M | $3.08M | $1.64M | $1.12M | $679,624 | $1.29M | $139,295 | $177,020 |
| Revenue Growth? | +9.6% | +56.9% | +41.5% | +88.4% | +46.0% | +65.1% | -47.3% | +825.0% | -21.3% | 0.0% |
| Cost of Revenue? | $10.45M | $7.22M | $217,155 | $187,672 | $295,630 | $200,818 | $56,088 | $53,119 | $25,514 | $16,658 |
| Gross Profit? | -$2.94M | -$366,768 | $4.15M | $2.90M | $1.34M | $920,909 | $623,536 | $1.24M | $113,781 | $160,362 |
| Gross Margin? | -39.1% | -5.4% | +95.0% | +93.9% | +81.9% | +82.1% | +91.7% | +95.9% | +81.7% | +90.6% |
| Operating Expenses? | $19.94M | $14.15M | $17.11M | $13.96M | $15.07M | $5.21M | $3.36M | $2.87M | $3.16M | $4.80M |
| Operating Income? | -$22.88M | -$22.05M | -$17.33M | -$14.15M | -$15.36M | -$5.41M | -$3.42M | -$2.92M | -$3.18M | -$4.82M |
| EBITDA? | -$20.33M | -$21.35M | -$16.99M | -$10.80M | -$14.77M | -$5.13M | -$2.68M | -$2.86M | -$3.16M | -$4.95M |
| Income Before Tax | -$21.43M | -$22.57M | -$17.39M | -$14.07M | -$15.08M | -$5.39M | -$3.47M | -$2.96M | -$3.16M | -$4.97M |
| Income Tax Expense | $0 | -$4.91M | -$4.31M | -$3.08M | -$1.57M | -$1.07M | -$679,624 | -$1.29M | -$139,295 | -$132,918 |
| Net Income? | -$21.43M | -$17.66M | -$13.08M | -$10.99M | -$13.51M | -$4.32M | -$2.79M | -$1.67M | -$3.03M | -$4.84M |
| EPS? | $-0.09 | $-0.10 | $-0.07 | $-0.06 | $-0.09 | $-0.03 | $-0.03 | $-0.02 | $-0.04 | $-0.09 |
| Diluted EPS? | $-0.09 | $-0.10 | $-0.07 | $-0.06 | $-0.09 | $-0.03 | $-0.03 | $-0.02 | $-0.04 | $-0.09 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality